Prot.ob, Ibkc, Icad, Icgn Stock Alerts! From Pennytobuck.com
Proteonomix, Inc
Proteonomix, Inc. (OTCBB:PROT.OB ) a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with its Joint Venture Company, XGEN Medical LLC towards implementing operations in the United Arab Emirates.
Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting Proteonomix personnel on Jumeira 2.
IBERIABANK Corporation (Nasdaq:IBKC) The Board of Directors of IBERIABANK Corporation announced the declaration of a quarterly cash dividend of $0.34 per share. The dividend is payable on October 29, 2010, to shareholders of record as of September 30, 2010. This dividend level equates to an annualized dividend rate of $1.36 per share. Based on the closing stock price on September 14, 2010, of $49.49 per share, IBKC had a market capitalization of approximately $1.3 billion and the indicated dividend yield was 2.75%.
IBERIABANK Corporation operates as the holding company for IBERIABANK that offers commercial and retail banking products and services in the United States. IBKC's deposit products primarily include NOW accounts, savings and money market accounts, and certificate of deposits. IBKC's loan portfolio comprises commercial loans, including real estate loans and business loans; mortgage loans consisting of residential one to four family loans and construction loans; and loans to individuals, such as indirect automobile loans and home equity loans.
iCAD, Inc. (NASDAQ:ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, recently announced that Ken Ferry, President and Chief Executive Officer and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, presented a corporate update at the Rodman & Renshaw 12th Annual Global Investment Conference on September 15, 2010 that was held at the New York Palace Hotel in New York City.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging and Computed Tomography. Since receiving FDA approval for ICAD's first breast cancer detection product in 2002, more than 3,800 iCAD systems have been placed in healthcare practices worldwide. iCADs solutions aid in the early detection of the most prevalent cancers including breast, prostate, and colon, and, in the future, lung cancer.
Icagen, Inc. (Nasdaq:ICGN) recently announced that due to the occurrence of a serious adverse event in the photosensitivity study of ICA-105665, ICGN has suspended further enrollment in the study. The serious adverse event occurred in the 600mg patient cohort following completion of the 500mg patient cohort. ICGN will be discussing the status of the study with its clinical advisors and with the FDA. Additionally, ICGN has completed the conduct of the multiple ascending dose study in healthy volunteers at daily doses of 500mg and 600mg for a period of seven days. There have been no serious adverse events noted, pending a final review of laboratory data. Analyses of the complete data set from both studies are ongoing.
Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. ICGN is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. ICGN has a clinical stage program in epilepsy and pain.
******************************************************************
For FREE Daily Stock Alerts & Updates Sign-up At: http://pennytobuck.com/signup
******************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
by: Bill Pennyman
Stop the BS and work your way to the next level! Lightning Pick Profiled by WTG Manufacturing and Supply Chain News Shock Absorbing Treadmills Save Wear And Tear On Joints How to Treat Warts-Causes and Types of Warts Frequenty Asked Question About Gerd And Ulcers Ansi Standards And Specifications Sytrinol- Benfits and Functioning A Fast And Simple Workout To Slim Your Waist Difference Between Botox And Juvederm Making a List and Checking it Twice Mutual Funds And Lessening Monetarily Contact Center Facts And Fallacies SmallCap Stocks Too Far Too Fast or Just the Beginning